Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results

por Stefoni, V, Casadei, B, Bottelli, C, Gaidano, G, Ciochetto, C, Cabras, M G, Ansuinelli, M, Argnani, L, Broccoli, A, Gandolfi, L, Pellegrini, C, Zinzani, P L
Publicado 2016